Cargando…
Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure
OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) gro...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602787/ https://www.ncbi.nlm.nih.gov/pubmed/34804911 http://dx.doi.org/10.3389/fonc.2021.639235 |
_version_ | 1784601632625917952 |
---|---|
author | Frangakis, Constantine Sohn, Jae Ho Bas, Ahmet Chapiro, Julius Schernthaner, Ruediger E. Lin, MingDe Hamilton, James P. Pawlik, Timothy M. Hong, Kelvin Duran, Rafael |
author_facet | Frangakis, Constantine Sohn, Jae Ho Bas, Ahmet Chapiro, Julius Schernthaner, Ruediger E. Lin, MingDe Hamilton, James P. Pawlik, Timothy M. Hong, Kelvin Duran, Rafael |
author_sort | Frangakis, Constantine |
collection | PubMed |
description | OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient. RESULTS: No significant change in PC over time was observed in either groups, regardless of liver function (P>0.05). Baseline spleen volume was 226 cm(3) for metastatic group, and was larger by 204 cm(3) for HCC group (P<0.001). Spleen volume increased by 20 cm(3) (95%CI: 8-32; P=0.001) for both groups after 1(st)TACE and by 16cm(3)/TACE (P=0.099) over the full follow-up (up to 9TACEs). Spleen volume also tended to increase by 23cm(3) (95%CI: -1–48; P=0.064) with higher tumor burden. Odds of developing moderate/severe ascites for metastatic patients was decreased by 0.5 (95%CI: 0.3–0.9; P=0.014), regardless of the Child-Pugh, and increased by 1.5 (95%CI: 1.2–1.9; P<0.001) among HCC patients with unstable Child-Pugh, whereas no change was noted with stable Child-Pugh. HCC patients with unstable Child-Pugh demonstrated a significant increase in portosystemic collaterals number over time (P=0.008). PVP-related complications such as variceal bleeding post-TACE were low (0.4%). CONCLUSION: Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications. |
format | Online Article Text |
id | pubmed-8602787 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-86027872021-11-20 Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure Frangakis, Constantine Sohn, Jae Ho Bas, Ahmet Chapiro, Julius Schernthaner, Ruediger E. Lin, MingDe Hamilton, James P. Pawlik, Timothy M. Hong, Kelvin Duran, Rafael Front Oncol Oncology OBJECTIVES: Investigate long-term effects of repeated transarterial chemoembolization (TACE) on portal venous pressure (PVP) using non-invasive surrogate markers of portal hypertension. METHODS: Retrospective, Institutional Review Board-approved study. 99 patients [hepatocellular carcinoma (HCC) group (n=57); liver metastasis group (n=42)] who underwent 279TACEs and had longitudinal pre-/post-therapy contrast-enhanced-MRI (n=388) and complete blood work were included. Outcomes of interest were platelet count (PC), spleen volume, ascites and portosystemic collaterals. Variables included TACE type/number, tumor type, microcatheter location, Child-Pugh, baseline tumor burden (tumor number/total/largest size), vessel invasion, alpha-fetoprotein, Eastern Cooperative Oncology Group (ECOG) performance status, and Model for End-Stage Liver Disease (MELD) score. Generalized Estimating Equations assessed the associations between TACE and outcomes. Power analysis determined the sample size was sufficient. RESULTS: No significant change in PC over time was observed in either groups, regardless of liver function (P>0.05). Baseline spleen volume was 226 cm(3) for metastatic group, and was larger by 204 cm(3) for HCC group (P<0.001). Spleen volume increased by 20 cm(3) (95%CI: 8-32; P=0.001) for both groups after 1(st)TACE and by 16cm(3)/TACE (P=0.099) over the full follow-up (up to 9TACEs). Spleen volume also tended to increase by 23cm(3) (95%CI: -1–48; P=0.064) with higher tumor burden. Odds of developing moderate/severe ascites for metastatic patients was decreased by 0.5 (95%CI: 0.3–0.9; P=0.014), regardless of the Child-Pugh, and increased by 1.5 (95%CI: 1.2–1.9; P<0.001) among HCC patients with unstable Child-Pugh, whereas no change was noted with stable Child-Pugh. HCC patients with unstable Child-Pugh demonstrated a significant increase in portosystemic collaterals number over time (P=0.008). PVP-related complications such as variceal bleeding post-TACE were low (0.4%). CONCLUSION: Repeated TACEs did seem to have an impact on PVP. However, the increase in PVP had marginal effects with low portal hypertension-related complications. Frontiers Media S.A. 2021-11-05 /pmc/articles/PMC8602787/ /pubmed/34804911 http://dx.doi.org/10.3389/fonc.2021.639235 Text en Copyright © 2021 Frangakis, Sohn, Bas, Chapiro, Schernthaner, Lin, Hamilton, Pawlik, Hong and Duran https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Frangakis, Constantine Sohn, Jae Ho Bas, Ahmet Chapiro, Julius Schernthaner, Ruediger E. Lin, MingDe Hamilton, James P. Pawlik, Timothy M. Hong, Kelvin Duran, Rafael Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title | Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title_full | Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title_fullStr | Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title_full_unstemmed | Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title_short | Longitudinal Analysis of the Effect of Repeated Transarterial Chemoembolization for Liver Cancer on Portal Venous Pressure |
title_sort | longitudinal analysis of the effect of repeated transarterial chemoembolization for liver cancer on portal venous pressure |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8602787/ https://www.ncbi.nlm.nih.gov/pubmed/34804911 http://dx.doi.org/10.3389/fonc.2021.639235 |
work_keys_str_mv | AT frangakisconstantine longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT sohnjaeho longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT basahmet longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT chapirojulius longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT schernthanerruedigere longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT linmingde longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT hamiltonjamesp longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT pawliktimothym longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT hongkelvin longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure AT duranrafael longitudinalanalysisoftheeffectofrepeatedtransarterialchemoembolizationforlivercanceronportalvenouspressure |